

EDD Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP2101b**Specification**

EDD Antibody (C-term) Blocking Peptide - Product InformationPrimary Accession [O95071](#)**EDD Antibody (C-term) Blocking Peptide - Additional Information**

Gene ID 51366

Other Names

E3 ubiquitin-protein ligase UBR5, 632-, E3 ubiquitin-protein ligase, HECT domain-containing 1, Hyperplastic discs protein homolog, hHYD, Progesterin-induced protein, UBR5, EDD, EDD1, HYD, KIAA0896

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP2101b](/product/products/AP2101b) was selected from the C-term region of human EDD. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

EDD Antibody (C-term) Blocking Peptide - Protein Information**Name** UBR5**Function**

E3 ubiquitin-protein ligase involved in different protein quality control pathways in the cytoplasm and nucleus (PubMed: [29033132](http://www.uniprot.org/citations/29033132), PubMed: [33208877](http://www.uniprot.org/citations/33208877), PubMed: [37478846](http://www.uniprot.org/citations/37478846), PubMed: [37478862](http://www.uniprot.org/citations/37478862)). Mainly acts as a ubiquitin chain elongator that extends pre-ubiquitinated substrates (PubMed: [29033132](http://www.uniprot.org/citations/29033132), PubMed: [37409633](http://www.uniprot.org/citations/37409633)). Component of the N-end rule pathway: ubiquitinates proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to

their degradation (By similarity). Recognizes type-1 N-degrons, containing positively charged amino acids (Arg, Lys and His) (By similarity). Together with UBR4, part of a cytoplasm protein quality control pathway that prevents protein aggregation by catalyzing assembly of heterotypic 'Lys-11'-'Lys-48'-linked branched ubiquitin chains on aggregated proteins, leading to substrate recognition by the segregase p97/VCP and degradation by the proteasome: UBR5 is probably branching multiple 'Lys-48'-linked chains of substrates initially modified with mixed conjugates by UBR4 (PubMed:29033132). Together with ITCH, catalyzes 'Lys-48'-'Lys-63'-branched ubiquitination of TXNIP, leading to its degradation: UBR5 mediates branching of 'Lys-48'-linked chains of substrates initially modified with 'Lys-63'-linked conjugates by ITCH (PubMed:29378950). Catalytic component of a nuclear protein quality control pathway that mediates ubiquitination and degradation of unpaired transcription factors (i.e. transcription factors that are not assembled into functional multiprotein complexes): specifically recognizes and binds degrons that are not accessible when transcription regulators are associated with their coactivators (PubMed:37478846, PubMed:37478862). Ubiquitinates various unpaired transcription regulator (MYC, SUPT4H1, SUPT5H, CDC20 and MCRS1), as well as ligand- bound nuclear receptors (ESR1, NR1H3, NR3C1, PGR, RARA, RXRA AND VDR) that are not associated with their nuclear receptor coactivators (NCOAs) (PubMed:33208877, PubMed:37478846, PubMed:37478862). Involved in maturation and/or transcriptional regulation of mRNA by mediating polyubiquitination and activation of CDK9 (PubMed:21127351). Also acts as a regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes (PubMed:22884692). Regulates DNA topoisomerase II binding protein (TopBP1) in the DNA damage response (PubMed:11714696). Ubiquitinates acetylated PCK1 (PubMed:21726808). Acts as a positive regulator of the canonical Wnt signaling pathway by mediating (1) ubiquitination and stabilization of CTNNB1, and (2) 'Lys- 48'-linked ubiquitination and degradation of TLE3 (PubMed:21118991, PubMed:28689657). Promotes disassembly of the mitotic checkpoint complex (MCC) from the APC/C complex by catalyzing ubiquitination of BUB1B, BUB3 and CDC20 (PubMed:35217622). Plays an essential role in extraembryonic development (By similarity). Required for the maintenance of skeletal tissue homeostasis by acting as an inhibitor of hedgehog (HH) signaling (By similarity).

Cellular Location

Nucleus. Cytoplasm

Tissue Location

Widely expressed. Most abundant in testis and expressed at high levels in brain, pituitary and kidney

EDD Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

EDD Antibody (C-term) Blocking Peptide - Images**EDD Antibody (C-term) Blocking Peptide - Background**

EDD is a progestin-induced protein, which belongs to the HECT (homology to E6-AP carboxyl terminus) family. The HECT family proteins function as E3 ubiquitin-protein ligases, targeting specific proteins for ubiquitin-mediated proteolysis. This gene is localized to chromosome 8q22, a locus disrupted in a variety of cancers. This gene potentially has a role in regulation of cell proliferation or differentiation.

EDD Antibody (C-term) Blocking Peptide - References

Clancy, J.L., et al., *Oncogene* 22(32):5070-5081 (2003). Henderson, M.J., et al., *J. Biol. Chem.* 277(29):26468-26478 (2002). Honda, Y., et al., *J. Biol. Chem.* 277(5):3599-3605 (2002). Callaghan, M.J., et al., *Oncogene* 17(26):3479-3491 (1998).